HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
— First randomized Phase III trial confirming the efficacy of MET inhibition…
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer
January 11, 2026 09:30 ET | Source: RxSight, Inc. ALISO VIEJO, Calif.,…
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
• Patient 1 of Cohort 1 has now completed the 24-month follow-up…
Varonis Announces Date of Fourth Quarter and Full-Year 2025 Financial Results
January 09, 2026 16:05 ET | Source: Varonis Systems, Inc. MIAMI, Jan.…
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
January 04, 2026 16:00 ET | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO,…
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026
January 02, 2026 16:05 ET | Source: Regeneron Pharmaceuticals, Inc. TARRYTOWN, N.Y.,…
Immutable Holdings Announces Voting Results for its Annual General and Special Meeting of Shareholders
December 31, 2025 18:02 ET | Source: Immutable Holdings Inc. VANCOUVER, British…
TraceLink Earns Top-Tier ISO, SOC, and CyberVadis Results, Confirming Its Position as the Most Trusted Agentic Orchestration Platform for Life Sciences
Independent audits and a Platinum CyberVadis rating demonstrate the rigor, resilience, and…
OBOOK Holdings Inc. Announces Unaudited Financial Results for the First Half of 2025 Ended June 30, 2025; Core Infrastructure Transition Near Completion; Enterprise Activation and Monetization
ARLINGTON, Va., Dec. 30, 2025 (GLOBE NEWSWIRE) -- OBOOK Holdings Inc. (NASDAQ:…
Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
The secondary analysis of the PACE trial highlights the value of counting…
